<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1906">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01652664</url>
  </required_header>
  <id_info>
    <org_study_id>C-12-008</org_study_id>
    <nct_id>NCT01652664</nct_id>
  </id_info>
  <brief_title>Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients</brief_title>
  <official_title>A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Singapore: Institutional Review Board</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>Taiwan: Research Ethics Committee</authority>
    <authority>Philippines: Ethics Committee</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>Saudi Arabia: Ethics Committee</authority>
    <authority>Colombia: Ethics Committee</authority>
    <authority>France: Ethics Committee</authority>
    <authority>Portugal: Ethics Committee for Clinical Research</authority>
    <authority>Belgium: Institutional Review Board</authority>
    <authority>Poland: Ethics Committee</authority>
    <authority>Romania: Ethics Committee</authority>
    <authority>Mexico: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of
      Travoprost 0.004% POLYQUAD (PQ) ophthalmic solution compared to Timolol ophthalmic solution
      (0.5% or 0.25%) in pediatric glaucoma patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Change From Baseline in IOP at Month 3</measure>
    <time_frame>Baseline (Day 0), Month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>IOP (fluid pressure inside the eye) was assessed using a calibrated tonometer and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye from each participant was chosen as the study eye and only the study eye was used for analysis.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Pediatric Glaucoma</condition>
  <condition>Elevated IOP in Pediatric Patients</condition>
  <condition>Ocular Hypertension in Pediatric Patients</condition>
  <arm_group>
    <arm_group_label>Travoprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost 0.004% PQ ophthalmic solution, 1 drop administered in each eye in the evening with travoprost vehicle administered once daily in the morning for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Timolol, 0.5% or 0.25% ophthalmic solution, 1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost 0.004% PQ ophthalmic solution</intervention_name>
    <arm_group_label>Travoprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol, 0.5% or 0.25% ophthalmic solution</intervention_name>
    <description>Patients 2 months to &lt; 3 years of age received 0.25%</description>
    <arm_group_label>Timolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost Vehicle</intervention_name>
    <description>Inactive ingredients used to maintain masking</description>
    <arm_group_label>Travoprost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of pediatric glaucoma or ocular hypertension.

          -  Qualifying mean IOP at the Eligibility Visit in at least one eye.

          -  Written informed consent, including assent when applicable, MUST be obtained from the
             parent or legally authorized representative prior to any procedure specified in the
             protocol, including screening procedures.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Females of childbearing potential who are pregnant, intend to become pregnant during
             the study period, breast feeding, or not using any form of birth control measures.

          -  History of chronic, recurrent or severe inflammatory eye disease.

          -  Ocular trauma requiring medical attention within the past 3 months prior to the
             Screening Visit.

          -  Ocular infection or ocular inflammation within the past 30 days prior to the
             Screening Visit.

          -  Clinically significant or progressive retinal disease.

          -  Severe ocular pathology (including severe dry eye) that, in the opinion of the
             Investigator, would preclude the administration of a topical prostaglandin analog or
             a topical beta-blocker.

          -  Intraocular surgery in the study eye within 30 days prior to the Screening Visit.

          -  Any abnormality preventing reliable applanation tonometry.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Subha Venkataraman, Clinical Project Lead</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 30, 2015</lastchanged_date>
  <firstreceived_date>July 26, 2012</firstreceived_date>
  <firstreceived_results_date>March 31, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cloprostenol</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from 38 investigational centers in the United States, Germany, Singapore, United Kingdom, Taiwan, Philippines, Spain, Saudi Arabia, Colombia, France, Portugal, Belgium, Poland, Romania, Puerto Rico, and Mexico.</recruitment_details>
      <pre_assignment_details>Of the 184 enrolled, 32 participants were exited as screen failures prior to randomization. This reporting group includes all randomized participants (152).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Travoprost</title>
          <description>1 drop administered in each eye in the evening with Travoprost vehicle in the morning for 3 months</description>
        </group>
        <group group_id="P2">
          <title>Timolol</title>
          <description>1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months; both concentrations of timolol (0.5% and 0.25%, based on age) were combined into a single group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inadequate IOP control</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all participants who received study drug and completed at least 1 scheduled on-therapy visit.</population>
      <group_list>
        <group group_id="B1">
          <title>Travoprost</title>
          <description>1 drop administered in each eye in the evening with Travoprost vehicle in the morning for 3 months</description>
        </group>
        <group group_id="B2">
          <title>Timolol</title>
          <description>1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months; both concentrations of timolol (0.5% and 0.25%, based on age) were combined into a single group.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="77"/>
                <measurement group_id="B2" value="75"/>
                <measurement group_id="B3" value="152"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>2 months to &lt;3 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="16"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>3 to &lt;12 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
                <measurement group_id="B2" value="39"/>
                <measurement group_id="B3" value="79"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>12 to &lt;18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="57"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
                <measurement group_id="B2" value="40"/>
                <measurement group_id="B3" value="80"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="72"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Intraocular Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="24.7" spread="4.62"/>
                <measurement group_id="B2" value="24.2" spread="4.01"/>
                <measurement group_id="B3" value="24.4" spread="4.32"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in IOP at Month 3</title>
        <description>IOP (fluid pressure inside the eye) was assessed using a calibrated tonometer and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye from each participant was chosen as the study eye and only the study eye was used for analysis.</description>
        <time_frame>Baseline (Day 0), Month 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>All participants who received study drug and completed at least 1 scheduled on-therapy visit. No imputation was used, therefore the analysis included only observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Travoprost</title>
            <description>1 drop administered in each eye in the evening with Travoprost vehicle in the morning for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Timolol</title>
            <description>1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months; both concentrations of timolol (0.5% and 0.25%, based on age) were combined into a single group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                  <measurement group_id="O2" value="74"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline in IOP at Month 3</title>
            <description>IOP (fluid pressure inside the eye) was assessed using a calibrated tonometer and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye from each participant was chosen as the study eye and only the study eye was used for analysis.</description>
            <units>mmHg</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-5.4" spread="0.98"/>
                  <measurement group_id="O2" value="-5.3" spread="0.93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected for the duration of the study (05 Sep 2012 - 25 Mar 2014). This analysis group includes all enrolled participants.</time_frame>
      <desc>An AE was defined as any untoward medical occurrence in a patient who is administered a study medication, regardless of whether or not the event has a causal relationship with the medication. All AEs were obtained as solicited comments from patients and as observations by the study Investigator as outlined in the study protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pre-Treatment</title>
          <description>All enrolled participants</description>
        </group>
        <group group_id="E2">
          <title>Travoprost</title>
          <description>All participants who received travoprost with vehicle</description>
        </group>
        <group group_id="E3">
          <title>Timolol</title>
          <description>All participants who received timolol; both concentrations of timolol (0.5% and 0.25%, based on age) were combined into a single group.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>medDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Keratitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>medDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Growth of eyelashes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Subha Venkataraman, Clinical Project Lead</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
